2.980EURMkt Cap: 56.15M EURP/E: —Last update: 2026-05-21
MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival. Its products pipeline includes MaaT013, that is in p…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap56.15M EUR
Enterprise Value48.73M EUR
Revenue (TTM)4.52M EUR
Gross Profit1.97M EUR
Net Income (TTM)-28.90M EUR
Revenue/Share0.2840 EUR
Last Price2.980 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees52
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0012634822
Valuation
P/E (Trailing)—
P/E (Forward)-2.88
PEG—
EV/EBITDA-1.66
EV/Revenue10.77
P/S12.41
P/B31.04
EPS (TTM)-2.15
EPS (Forward)-1.03
52W Range
2.60058% of range3.250
52W High3.250 EUR
52W Low2.600 EUR
Profitability
Gross Margin61.13%
Oper. Margin-714.35%
EBITDA Margin0.00%
Profit Margin-898.76%
ROE-279.64%
ROA-75.07%
Growth
Revenue Growth40.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-22.04M EUR
CapEx (TTM)753.00K EUR
FCF Margin-313.01%
FCF Yield-25.22%
Net Debt-7.43M EUR
Net Debt/EBITDA0.25
Balance Sheet
Debt/Equity1.54
Current Ratio1.94
Quick Ratio1.87
Book Value/Sh0.0960 EUR
Cash/Share1.320 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)16.00 EUR
Target Range12.00 EUR – 19.00 EUR
# Analysts5
Ownership
Shares Out.18.84M
Float9.87M
Insiders22.10%
Institutions47.75%
Technical
SMA 506.261 (-52.4%)
SMA 2005.350 (-44.3%)
Beta0.46
S&P 52W Chg27.23%
Avg Vol (30d)1.05M
Avg Vol (10d)130.21K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—